US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VIRI

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
21/11/2024	08:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRI	Virios Therapeutics Inc
08/11/2024	07:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIRI	Virios Therapeutics Inc
17/10/2024	15:30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VIRI	Virios Therapeutics Inc
15/10/2024	15:19	Edgar (US Regulatory)	Form SC 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:VIRI	Virios Therapeutics Inc
07/10/2024	07:06	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:VIRI	Virios Therapeutics Inc
07/10/2024	06:05	GlobeNewswire Inc.	Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)	NASDAQ:VIRI	Virios Therapeutics Inc
08/08/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics Announces Second Quarter 2024 Financial Results	NASDAQ:VIRI	Virios Therapeutics Inc
01/08/2024	08:41	GlobeNewswire Inc.	Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024	NASDAQ:VIRI	Virios Therapeutics Inc
23/07/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center	NASDAQ:VIRI	Virios Therapeutics Inc
22/05/2024	12:30	GlobeNewswire Inc.	Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	NASDAQ:VIRI	Virios Therapeutics Inc
20/05/2024	15:05	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:VIRI	Virios Therapeutics Inc
19/05/2024	19:53	GlobeNewswire Inc.	Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	NASDAQ:VIRI	Virios Therapeutics Inc
17/05/2024	15:10	GlobeNewswire Inc.	Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	NASDAQ:VIRI	Virios Therapeutics Inc
09/05/2024	06:45	GlobeNewswire Inc.	Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:VIRI	Virios Therapeutics Inc
02/05/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	NASDAQ:VIRI	Virios Therapeutics Inc
26/03/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID	NASDAQ:VIRI	Virios Therapeutics Inc
08/03/2024	16:00	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:VIRI	Virios Therapeutics Inc
01/03/2024	08:10	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:VIRI	Virios Therapeutics Inc
29/02/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:VIRI	Virios Therapeutics Inc
28/02/2024	12:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRI	Virios Therapeutics Inc
28/02/2024	08:15	GlobeNewswire Inc.	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	NASDAQ:VIRI	Virios Therapeutics Inc
02/02/2024	15:31	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VIRI	Virios Therapeutics Inc
22/01/2024	08:33	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:VIRI	Virios Therapeutics Inc
22/01/2024	08:00	GlobeNewswire Inc.	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID	NASDAQ:VIRI	Virios Therapeutics Inc
02/01/2024	06:05	GlobeNewswire Inc.	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	NASDAQ:VIRI	Virios Therapeutics Inc
13/11/2023	06:05	GlobeNewswire Inc.	Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:VIRI	Virios Therapeutics Inc
06/11/2023	06:05	GlobeNewswire Inc.	Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	NASDAQ:VIRI	Virios Therapeutics Inc
12/10/2023	06:05	GlobeNewswire Inc.	Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023	NASDAQ:VIRI	Virios Therapeutics Inc
18/09/2023	06:05	GlobeNewswire Inc.	Virios Therapeutics Announces Termination of At-The-Market Sales Agreement	NASDAQ:VIRI	Virios Therapeutics Inc
12/09/2023	06:05	GlobeNewswire Inc.	Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023	NASDAQ:VIRI	Virios Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:VIRI

1 2 3 4 Próxima >

Deutsche Telekom (QX)

Verizon Communications

Health Care Select Sector

JP Morgan Chase

Euro vs US Dollar

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones